Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03803709
Other study ID # 190616V1
Secondary ID 2017/04JUL/354
Status Recruiting
Phase N/A
First received
Last updated
Start date July 4, 2017
Est. completion date July 2022

Study information

Verified date December 2018
Source Université Catholique de Louvain
Contact Peter Stärkel, MD, PhD
Phone 003227642853
Email peter.starkel@uclouvain.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The alcohol problem affects 7.5% of the population in Europe and represents a major public health problem. Alcoholism is also a major cause of undernutrition. Diet is a major factor influencing the composition of the intestinal microbiota and previous studies, carried out at Saint-Luc clinics and catholic university of Louvain, show that alcoholic patients suffer from dysbiosis, that is a significant alteration of the gut microbiota. The investigator's preliminary studies, carried out at the Integrated Unit of Hepatology of Saint-Luc Clinics, have shown that alcohol represents more than 40% of total caloric intake in alcohol-dependent patients. In addition, alcoholic patients have an insufficient intake of dietary fiber, that is to say a contribution lower than the Belgian nutritional recommendations. Indeed, the Conseil Supérieur de la Santé recommends a total amount of dietary fiber equal to or greater than 25 grams per day to ensure correct intestinal function. Fructan-type dietary fiber (inulin and fructo-oligosaccharides) is found naturally in many fruits and vegetables (Jerusalem artichokes, asparagus, artichokes, onions, garlic, chicory roots, bananas). They are neither absorbed nor digested by human enzymes but fermented selectively by intestinal bacteria.

A good digestive tolerance to dietary fiber supplementation has been observed in healthy subjects as well as in obese patients, in previous studies conducted at catholic university of Louvain and Saint-Luc clinics. However, a nutritional rebalance via fiber supplementation and digestive fiber tolerance have never been tested in an alcohol-dependent population.

The primary objectives of this academic research project in nutrition, carried out in alcohol-dependent patients, are as follows:

1. restore a nutritional balance as recommended by the Conseil Supérieur de la Santé via a dietary fiber intake

2. to study digestive tolerance to fibers

3. to study the intestinal and psychological well-being related to a fiber intake

Depending on the results obtained during the achievement of the primary objectives, the biological samples (blood, stool) collected during the study will be used to analyze the composition of the intestinal microbiota and the plasma markers associated with intestinal function.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 2022
Est. primary completion date July 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- male or female

- aged between 18 and 65

- caucasian

- French speaking

- alcohol drunk less than 48h before day 1

Exclusion Criteria:

- another addiction, except smoking

- psychiatric comorbidity on axe 1 of Diagnostic and Statistical Manual-IV

- antibiotic, probiotic or fibers recent (<2 months) treatment (or other molecule modifying intestinal transit)

- Non-steroidial anti-inflammatory drug or glucocorticoids recently taken (<1 month)

- obesity: Body Mass Index<30

- bariatric surgery

- Type 1 or 2 diabetes

- chronic inflammatory diseases (Crohn disease, coeliac disease, rheumatoid arthritis)

- cirrhosis or Advanced hepatic fibrosis (Fibroscan > or = F3)

- pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
inulin
inulin given at different dosis from day 3 to day 20
placebo
maltodextrine given at different dosis from day 3 to day 20

Locations

Country Name City State
Belgium Université catholique de Louvain Brussels

Sponsors (1)

Lead Sponsor Collaborator
Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in diet profile This tool is based on the one adapted to alcoholic patients at Saint Luc Hospital. It consists of two parts to allow cross-checking of data (redundancy) and to measure separate information:
General: it is implemented a Food Frequency Questionnaire (FFQ) in order to investigate the general diet profile.
Daily: it resumes the sequencing of a full day which allows to verify the information previously obtained as well as to precisely identify the moments of consumption of alcoholic and non-alcoholic inputs.
This 7-day recall will be carried out at two times: week T1 for reminder of the week before hospitalization then T2 for reminder of the week back home. In this last case, this anamnesis will be done by interview, but also on the basis of the diary filled by the patient in T2, in order to optimize the accuracy of the data.
on Day 2 and Day 19
Secondary Alimentary book The patient will have to fill in this book every day From day 1 to day 21
Secondary Quantitative evaluation of intakes The meals will be weighted before and after eating on Day 2 and Day 19
Secondary Alimentation history This questionnaire makes it possible to further investigate the patient's diet before the episode of alcoholism in his adult and child life. The aim is to assess whether it is closer to a healthy diet (Mediterranean diet or dash diet) or a Western diet type. It is based on the recall technique and performed by a qualified dietician. On day 21
Secondary Change in mood Beck Depression Inventory (score 0-63). Higher score indicates higher depression level. on Day 2 and Day 19
Secondary Change in anxiety State-Trait Anxiety Inventory (score 20-80). Higher score indicates higher anxiety level. on Day 2 and Day 19
Secondary Change in alcohol craving Obsessive Compulsive Drinking Scale: a total score (= obsession + compulsion) (0-40) and 2 sub-scores (Obsession (0-20) and Compulsion (0-20)) are calculated. Higher score indicates higher craving level. on Day 2 and Day 19
Secondary Change in impulsivity Urgency Premeditation Perseverance Sensation seeking impulsive behavior scale: score of different subscales are calculated: "urgency"(0-48), "lack of premeditation"(0-44), "lack of perseverance"(0-40), "sensation seeking"(0-48). Higher score in the different subscales indicates higher impulsivity level. on Day 2 and Day 19
Secondary Change in selective attention William Lennox attention tests on Day 2 and Day 19
Secondary Change in work memory Brown-Peterson's tasks on Day 2 and Day 19
Secondary Change in flexibility Trail making test on Day 2 and Day 19
Secondary Change in inhibition Scoop's tasks on Day 2 and Day 19
Secondary Change in decision making Iowa gambling's task on Day 2 and Day 19
Secondary Change in trauma Post-traumatic diagnostic scale: calculation of score is complex and described in the related publication Hearn, M, Ceschi, G., Brillon, P, Fürst, G., & Van der Linden, M. (2012). A French adaptation of the Post-traumatic Diagnostic scale. Canadian Journal of Behavioural Science, 44, 16-28. on Day 2 and Day 19
Secondary Change in intestine integrity It will be determined by blood sample (LPS level) on Day 2 and Day 19
Secondary Change in albumin, pre-albumin and zinc concentration It will be determined by blood sample on Day 2 and Day 19
Secondary Change in intestinal permeability Patients will ingest 50microCurie of 51Chrome-Ethylenediamintetraacetic prepared in a Nutridrink®. This molecule is not normally absorbed by the intestine except when there is an increase in intestinal permeability (paracellular passage following rupture of tight junctions). The molecule is then filtered by the kidney and is found in the urine. A 24h urine collection will be carried out to measure the radioactivity emitted by 51Chrome-Ethylenediamintetraacetic on Day 2 and Day 19
Secondary Change in fecal albumin concentration A stool sample will be collected to analyze a marker of intestinal permeability: fecal albumin on Day 2 and Day 19
Secondary Intestinal permeability a duodenal biopsy will be collected and the expression of the tight junctions regulating the intestinal permeability will be analyzed by sectional immunofluorescence and quantitative Polymerase Chain reaction On day 3
See also
  Status Clinical Trial Phase
Recruiting NCT05054738 - CRP and S&A for Inpatient Veterans N/A
Completed NCT02233738 - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services N/A
Completed NCT05877807 - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT00536146 - The Stress-Hormone System in Alcohol-Dependent Subjects N/A
Terminated NCT00890149 - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults Phase 2
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT01553136 - Varenicline Treatment of Alcohol Dependence in Smokers Phase 2
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01389297 - Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery N/A
Completed NCT00768508 - Combined Pharmacotherapies for Alcoholism Phase 3
Completed NCT01113164 - Matching Genotypes and Serotonergic Medications for Alcoholism Phase 1
Completed NCT01760785 - Valproate for Mood Swings and Alcohol Use Following Head Injury N/A
Terminated NCT02842528 - Cognitive Vulnerability Factors in Alcohol-dependence N/A
Completed NCT00127231 - Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women N/A
Completed NCT00367575 - An Internet-based Intervention for Problem Drinking N/A
Completed NCT00583440 - 12-step Facilitation for the Dually Diagnosed Phase 1/Phase 2
Completed NCT00223639 - New Medications to Treat Alcohol Dependence Phase 2
Completed NCT00167687 - Prazosin Alcohol Dependence IVR Study Phase 4